Related Experiment Video
Updated: Aug 5, 2025
07:39
Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
Published on: August 16, 2021
3.7K
Bridging with surgically placed microaxial left ventricular assist devices: a high-volume centre experience
George Gill1, Georgina Rowe1, Qiudong Chen1
1Department of Cardiac Surgery, Cedars-Sinai Medica Center, Los Angeles, CA, USA.
Summary
The Impella 5.0 and 5.5 devices offer safe and effective temporary mechanical support for cardiogenic shock patients. The Impella 5.5 shows a potential reduction in device exchanges compared to the Impella 5.0.
Area of Science:
- Cardiology
- Mechanical Circulatory Support
Background:
- The Impella 5.0 and 5.5 are advanced temporary mechanical circulatory support devices.
- Clinical outcome data for these devices are primarily from small case series.
- This study details the experience from a high-volume center.
Purpose of the Study:
- To evaluate the clinical outcomes and safety of Impella 5.0 and 5.5 devices in patients with cardiogenic shock.
- To compare the performance of Impella 5.5 versus Impella 5.0 in a real-world, high-volume setting.
Main Methods:
- Retrospective analysis of an institutional clinical registry.
- Inclusion criteria: patients with cardiogenic shock receiving Impella 5.0 or 5.5 implantation (January 2014 - March 2022).
- Primary outcome: survival to device explantation.
Main Results:
- A cohort of 221 patients (146 Impella 5.0, 75 Impella 5.5) was analyzed.
- Common etiologies included non-ischaemic cardiomyopathy (50.7%) and acute myocardial infarction (26.2%).
- Overall survival to explantation was 70.1%. Impella 5.5 showed lower device exchange rates (4.0% vs 13.3%, P=0.04) compared to recent Impella 5.0 cases.
Conclusions:
- Impella 5.0 and 5.5 devices are safe and effective for temporary mechanical support in selected cardiogenic shock patients.
- The Impella 5.5 may offer an advantage with a reduced need for device exchange.
